As finalized in the CY 2025 OPPS/ASC final rule with comment period (89 FR 93955), starting in the OPPS/ASC rulemaking for CY 2026 and for subsequent years, we stated we would update the proposed threshold amount of $630 by a forecast of the PPI for Pharmaceuticals for Human Use, Prescription (BLS series code WPUSI07003) from IHS Global, Inc (IGI) by using most recently available four-quarter moving average PPI levels to trend from the third quarter of the year 2 years prior to the applicable calendar year to the third quarter of the year prior ( to the applicable calendar year (for example, from the third quarter of 2024 to the third quarter of 2025 for CY 2026)
AOD-9604 does not protect against the hormonal consequences of severe restriction the way GLP-1 agonists do
Sermorelin is a growth hormone-releasing hormone analog
IV add-ons are targeted injections or nutrient boosts that enhance your IV drip by addressing specific wellness goals such as energy, immunity, hydration, or recovery
After consideration of comments, we are finalizing increased burden estimates found in section XXIII., Collection of Information Requirements, of this final rule with comment period
Plan for 4-8 weeks minimum
